NexGenix Pharmaceuticals Holdings Inc., a New York-based developer drugs to treat neurofibromatosis and related sporadic tumors, has raised $3.9 million in Series B funding. No investor information was disclosed. www.nexgenixpharm.com
NexGenix Pharmaceuticals Holdings Inc., a New York-based developer drugs to treat neurofibromatosis and related sporadic tumors, has raised $3.9 million in Series B funding. No investor information was disclosed. www.nexgenixpharm.com
Copyright PEI Media
Not for publication, email or dissemination